Radiopharm Theranostics announced that the US Food & Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for its DUNP19 technology for the treatment of osteosarcoma. The RPD program is aimed at advancing development of drugs with the potential to treat serious, rare pediatric diseases. RPD allows companies to receive a priority review voucher (PRV) from the FDA at the time a marketing authorization is granted.

A PRV can be used by the Company to expedite approval, or can be transferred/sold to other companies for use in the same manner. The price of two recent examples of PRVs sales have ranged from USD 105,000 to USD 110,000.